VALNEVA Declaration of shares and voting rights: January 31, 2026
VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name:…
Coloplast A/S – Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast…
Pluristyx and Solesis Launch First-of-its-Kind PluriForm-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
New ready-to-use kit combines Pluristyx’s high-quality pluripotent cells and mRNA technology with…
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
February 05, 2026 07:01 ET | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE…
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026 07:00 ET | Source: Dianthus Therapeutics, Inc. NEW YORK…
Phaos Technology Holdings (Cayman) Limited Provides Response to Unusual Market Action
SINGAPORE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited,…
NETCLASS TECHNOLOGY INC Advances AI Business with Phased Progress
Signed $1.67 million AI-service order, representing initiative in AI applicationLaunched AI-Powered CEPA…
Trillion-Yuan Innovation Hub Empowers Growth, SIXUNITED Targets RMB 10 Billion Revenue and 15 Million AI Terminals by 2026
SHANGHAI, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Recently, the Sixth Session of…
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast…
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its…
